Summary: Dupilumab is a fully human antiinterleukin-4-receptor α (IL-4Rα) monoclonal antibody, which inhibits interleukin 4 (IL-4) and interleukin 13 (IL-13) signalling key drivers of type-2-mediated inflammation. Dupilumab is dedicated for patients with severe asthma which remains uncontrolled despite maximal inhaled corticosteroids therapy and at least one controller. A numer clinical trials have proved the efficacy and the safety of dupilumab use in patients with severe uncontrolled asthma. Dupilumab significantly reduced severe exacerbations and improved lung function and asthma control in patients with type 2 asthma on high-dose ICS at baseline.